Showing 2761-2770 of 7016 results for "".
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
https://reachmd.com/programs/cme/optimize-outcomes-in-ckd-t2d-a-practical-approach-to-initiating-and-monitoring-combination-ns-mra-sglt2i-therapy/29904/Time is nephron mass! Learn how nephrologists apply CONFIDENCE data & 4-pillar therapy to transform CKD + T2D care in this real-world case.Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/why-words-matter-rethinking-terminology-in-advanced-prostate-cancer/32222/Inconsistent or stigmatizing terminology like “castration-resistant prostate cancer” can hinder both clinical clarity and patient acceptance of life-prolonging therapies, underscoring the importance of utilizing more accurate, sensitive terms like “androgen deprivation resistant prostate cancer.” HeNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/new-frontiers-in-the-imaging-and-treatment-of-advanced-prostate-cancer/32221/From PSMA imaging to precision medicine strategies based on molecular drivers, novel diagnostics and therapies are reshaping the way we care for men with advanced prostate cancer. But despite these advancements, certain challenges and unmet needs remain. Joining Dr. Wayne Kuang to talk about these eOral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
https://reachmd.com/programs/project-oncology/oral-contraceptives-and-endometrial-cancer-examining-a-potential-dose-response-protective-effect/35506/As rates of endometrial cancer rise globally, a 2025 meta-analysis offers compelling evidence that oral contraceptives (OCs) could significantly reduce EMC risk. Explore the findings from this new review and its potential implications for the future of patient care.Fatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
https://reachmd.com/programs/neurofrontiers/fatigue-in-multiple-sclerosis-investigating-longitudinal-determinants/17931/Discover the sociodemographic, clinical, and therapeutic factors that drive long-term fatigue in multiple sclerosis patients and strategies for managing it.Caring for Women with MS: Key Considerations for Pregnancy and Menopause
https://reachmd.com/programs/neurofrontiers/caring-for-women-with-ms-key-considerations-for-pregnancy-and-menopause/32368/Read about unique challenges for women with multiple sclerosis and key considerations for pregnant and menopausal patients.Respiratory Syncytial Virus: New Vaccines for Infants and Adults
https://reachmd.com/programs/idsa-action-center/respiratory-syncytial-virus-new-vaccines-for-infants-and-adults/16102/Tune in for more updates about the first FDA-approved vaccines for RSV. Here’s what we know.The Impact of RADIANT: A Deep Dive into the Study
https://reachmd.com/programs/diabetes-discourse/the-impact-of-radiant-a-deep-dive-into-the-study/15883/How do we treat patients with rare and atypical diabetes? Dive into the key findings from the RADIANT study.Mitigating Risk in New IBD Treatments– IBD Pro Webinar Series
https://reachmd.com/programs/cme/mitigating-risk-in-new-ibd-treatments-ibd-pro-webinar-series/16004/Join us for this module of the IBD Pro Webinar Series presentation titled “How to Mitigate Risks in New Therapies”. The talk will include new medications, positioning, real world evidence, and the Foundation's EMR IBD Education Tool. The 45 minute presentation will be followed by a 15 minute quesNew Treatments in IBD – Professional Webinar Series
https://reachmd.com/programs/cme/new-treatments-in-ibd-professional-webinar-series/15694/Join us for this module of the IBD Pro Webinar Series presentation titled “New Treatments in IBD”. The talk will include new medications, positioning, real world evidence, and the Foundation's EMR IBD Education Tool. The 45 minute presentation will be followed by a 15 minute question and answer s